Xist lncRNA identified as key trigger in female-biased autoimmune diseases

In a recent study published in the journal Cell, a team of scientists predominantly from Stanford University discovered that sex-biased autoimmunity, where females are more affected by autoimmune disorders than males, is primarily driven by the Xist ribonucleoprotein complex containing various autoantigenic components.

Study: Xist ribonucleoproteins promote female sex-biased autoimmunity. Image Credit: Kateryna Kon / ShutterstockStudy: Xist ribonucleoproteins promote female sex-biased autoimmunity. Image Credit: Kateryna Kon / Shutterstock

Background

After cancer and cardiovascular disease, autoimmune disorders are the most prevalent category of disease, with females having a four-fold higher incidence of autoimmune diseases than males. Sjögren’s disease has a 19 to one female to male prevalence, while the sex ratio of systemic lupus erythematosus patients is 9:1 for females to males. Furthermore, Klinefelter syndrome patients who have XXY sex chromosomes and are phenotypically male with hormonal patterns of a biological male also have the same risk of autoimmune disorders as females.

While the role of hormones has been extensively studied in relation to autoimmune disorders, research indicates that irrespective of hormone status and sex, X chromosome dosage seems to be one of the major drivers of autoimmune disease risk. Additionally, studies among identical twins indicate that the penetrance of autoimmune disease can also vary, suggesting that environmental factors can influence the genetic disposition to autoimmune disorders. X-linked genes such as toll-like receptor 7 (TLR7) have been thought to contribute to the development of some autoimmune disorders.

About the study

In the present study, the researchers used autoimmune-resistant and autoimmune-prone mouse models, C57BL/6J and SJL/J, respectively, to understand the role of X chromosome dosage compensation in determining the disproportionate risk of autoimmune diseases in females.

Since mammalian females have two copies of the X chromosomes as compared to mammalian males, who have an XY genotype, one of the two X chromosomes in females is epigenetically silenced for dosage compensation in every cell through a mechanism involving a 19-kb pair long non-coding ribonucleic acid (lncRNA) called Xist. Xist is not expressed in males,  and only the inactive X chromosome transcribes this lncRNA in females.

Studies in embryonic stem cells from mice have shown that X chromosome inactivation is established when Xist forms a ribonucleoprotein complex with 81 binding proteins that are unique to this complex. Xist binds directly to 10 of these binding proteins through RNA-protein interactions, and to the remaining 71 indirectly through protein-protein interactions. Several of these binding proteins have previously been identified as autoantigens and are thought to activate innate immune system pathways through toll-like receptors.

Here, the researchers used non-silencing alleles of Xist that were inducible and introduced them into the autosomes of the autoimmune-resistant and autoimmune-prone mice strains. The induction of Xist ribonucleoprotein complex formation in male mice of a chemically induced systemic lupus erythematosus mouse model allowed this female-specific process to be observed in a male background.

RNA sequencing and ATAC-sequencing or assay of transposase-accessible chromatin by sequencing were used to assess changes in gene expression in splenic CD4+ T cells and potential transcription regulation alterations. Principal component analysis was also used to determine similarities between male mice expressing the induced Xist allele.

Serum samples from treated mice were also assessed for antigens against scleroderma and systemic lupus erythematosus. Additionally, serum samples obtained from human patients of systemic lupus erythematosus, dermatomyositis, and scleroderma were tested for reactivity against proteins from the Xist ribonucleoprotein complex.

Results

The results reported that the induction of transgenic expression of non-silenced Xist in male mice formed Xist ribonucleoprotein complexes and led to the production of autoantibodies. Male autoimmune-prone mice models of pristane-induced systemic lupus erythematosus showed multi-organ pathology that was more severe than that seen in the wild-type mice. Furthermore, the expression of Xist in the male mice had reprogrammed the chromatic states and the B and T cell populations to be more similar to those found in wild-type female mice.

The reactivity against multiple proteins from the Xist ribonucleoprotein complex was also found to be significant in the serum samples obtained from human systemic lupus erythematosus, dermatomyositis, and scleroderma patients.

The findings highlight the potential for using these Xist ribonucleoprotein complex-associated proteins as novel antigens for detecting and monitoring autoimmune diseases. The discovery of atypical B cell accumulation due to Xist ribonucleoprotein complex expression also provides a potential area of research for autoimmune disorder therapy.

Conclusions

Overall, the findings indicated that the Xist ribonucleoprotein complex selectively expressed in females and involved in X chromosome dosage compensation drives sex-biased autoimmunity. Patients with autoimmune conditions such as scleroderma and systemic lupus erythematosus have higher reactivity against proteins from the Xist ribonucleoprotein complex, highlighting the potential use of these proteins as antigens for screening and early detection of autoimmune disorders.

Journal reference:
  • Dou, D. R., Zhao, Y., Belk, J. A., Zhao, Y., Casey, K. M., Chen, D. C., Li, R., Yu, B., Srinivasan, S., Abe, B. T., Kraft, K., Hellström, C., Sjöberg, R., Chang, S., Feng, A., Goldman, D. W., Shah, A. A., Petri, M., Chung, L. S., & Fiorentino, D. F. (2024). Xist ribonucleoproteins promote female sex-biased autoimmunity. Cell, 187(3), 733-749.e16, 10.1016/j.cell.2023.12.037, https://www.cell.com/cell/fulltext/S0092-8674(24)00002-3
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2024, February 04). Xist lncRNA identified as key trigger in female-biased autoimmune diseases. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20240204/Xist-lncRNA-identified-as-key-trigger-in-female-biased-autoimmune-diseases.aspx.

  • MLA

    Sidharthan, Chinta. "Xist lncRNA identified as key trigger in female-biased autoimmune diseases". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20240204/Xist-lncRNA-identified-as-key-trigger-in-female-biased-autoimmune-diseases.aspx>.

  • Chicago

    Sidharthan, Chinta. "Xist lncRNA identified as key trigger in female-biased autoimmune diseases". News-Medical. https://www.news-medical.net/news/20240204/Xist-lncRNA-identified-as-key-trigger-in-female-biased-autoimmune-diseases.aspx. (accessed October 31, 2024).

  • Harvard

    Sidharthan, Chinta. 2024. Xist lncRNA identified as key trigger in female-biased autoimmune diseases. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20240204/Xist-lncRNA-identified-as-key-trigger-in-female-biased-autoimmune-diseases.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New pro-oxidant supplement shows promise in slowing prostate cancer progression